3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
21
Pancreatic Neoplasms
10
Colonic Neoplasms
9
Burkitt Lymphoma
8
Adenocarcinoma Of Esophagus
7
Stomach Neoplasms
6
Rectal Neoplasms
6
Neoplasm Metastasis
5
Esophageal Neoplasms
5
Cholangiocarcinoma
5
Carcinoma, Non-Small-Cell Lung
5
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
4
Neoplasms
4
Leukemia, Biphenotypic, Acute
4
Adenocarcinoma
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Lung Neoplasms
3
Gallbladder Neoplasms
3
Endometrial Neoplasms
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Ovarian Neoplasms
2
Esophageal Squamous Cell Carcinoma
2
Down Syndrome
2
Carcinoma, Hepatocellular
2
Advanced Solid Tumors
2
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Solid Tumors
1
Small Bowel Adenocarcinoma
1
Interventions
durvalumab
2
Specimen Handling
2
Magnetic Resonance Spectroscopy
2
Gemcitabine
2
Cisplatin
2
trametinib
1
tivozanib
1
olaparib
1
Stents
1
Oxaliplatin
1
Nivolumab
1
Leucovorin
1
Ipilimumab
1
Folfox protocol
1
Fluorouracil
1
Floxuridine
1
Dexamethasone
1
CTLA-4 Antigen
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Bile Duct Neoplasms
×
Leucovorin
×
30 days
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts